Abstract
The 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidemia guidelines have recalibrated targets of lipid-lowering therapy, particularly for secondary prevention. In patients (pts) with coronary heart disease considered very high risk, a low-density lipoprotein cholesterol
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
